Blog

Present and Future of IBSA Farmaceutici on Chemistry Today

Chemistry Today – international magazine of the chemical and pharmaceutical field – tells the present and the future of IBSA, in the current national and global vision. At the most important fair dedicated to the Pharmaceutical Industry, CPhI Worldwide in Milan from 9 to 11 November, the Company will attend the event with an important stand to meet all its partners.

Luca Crippa’s Interview

The visionary leadership of the Founder Arturo Licenziati allowed IBSA to transform itself, from a small Swiss laboratory in the 1940s, into a top-level global company for the pharmaceutical field. Thanks to its industrial capacity and proprietary technologies, IBSA exports scientific know-how and the “Made in Italy” excellence in the world.
82 patent families,10 therapeutic areas and more than 1600 employees are just some of the numbers that testify to the great commitment of the Company over the years.

Luca Crippa – CEO & Managing Director of IBSA Farmaceutici – told Chemistry Today that the Company, despite the pandemic, has confirmed an investment plan of € 15 million aimed at technological implementation, production expansion and the development of sustainable solutions supporting the Health System.

Among the challenges of IBSA Farmaceutici, there is the development of new products and technologies in four main areas – Fertility, Endocrinology, Osteoarticular and Aesthetic Medicine – and the search for new international partners for the production and distribution of its products.

Infact, the CPhI Worldwide, which after fourteen years returns to Italy, is an important event to share the global vision and the competitive capacity in a context of excellence such as that of the Lombard pharmaceutical industry, the first region for industrial presence with over 100 companies, 24,000 direct employees and over 28,000 in related fields.

Related Articles
+
05.03.2024
OSTEOARTHRITIS AND VISCOSUPPLEMENTATION – Advertorial – Chemistry today
Osteoarthritis, the most common cause of musculoskeletal disability. Let’s find out more with the IBSA NAHYCO® HYBRID TECHNOLOGY.
+
05.03.2024
OSTEOARTHRITIS AND VISCOSUPPLEMENTATION – Advertorial – Chemistry today
Osteoarthritis, the most common cause of musculoskeletal disability. Let’s find out more with the IBSA NAHYCO® HYBRID TECHNOLOGY.
+
31.10.2023
A word with Andrea Taborelli – Interview with Chimica Oggi – Chemistry Today
Andrea Toborelli, Business Development and Licensing Manager at IBSA, was interview by Nutra Horizons. 
We’re looking for partners and international distributors for our products.
GET IN TOUCH WITH US
logo-footer

Headquarter

 

Via del Piano 29,
6926 Collina d’Oro,
Switzerland
Tel. +41 58 360 10 00

 

 

 

Follow us